Cytokinetics, Inc. ( CYTK ) shares are trading lower by 17.6% to $48.83 during Thursday’s session after the company announced the pricing of a public offering of 9,803,922 shares of its common stock at $51.00 per share, expecting to raise approximately $500 million before expenses.

The offering is set to close on May 28, 2024, pending standard conditions. Additionally, Cytokinetics ( CYTK ) has granted the underwriters a 30-day option to buy up to an extra 1,470,588 shares at the same price.

J.P. Morgan, Goldman Sachs and Morgan Stanley are managing the offering.

See Also: VanEck’s Spot Ethereum ETF Listed On DTCC As SEC Decision Looms

Is CYTK A Good Stock To Buy?

An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages – like Cytokinetics ( CYTK )‘s page for example – there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.

These are known as capital allocation programs. Cytokinetics ( CYTK ) does not pay a dividend, but obviously has a few ways it can return value to shareholders. Feel free to search Benzinga's dividend calendar for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.

Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on Cytokinetics ( CYTK ) will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.

According to data from Benzinga Pro, CYTK has a 52-week high of $110.25 and a 52-week low of $25.98.